Core Viewpoint - Hagens Berman is alerting investors about a pending class action against CoreWeave, Inc. (NASDAQ: CRWV) for allegedly misleading the market regarding its AI infrastructure scalability and revenue guidance [1][3] Allegations of Misrepresentation - The lawsuit claims that CoreWeave overstated its capacity to meet customer demand and downplayed operational risks associated with reliance on a single third-party data center supplier [2][6] - Significant delays at the Denton, Texas data center were concealed, with completion pushed back by several months due to construction hurdles, contradicting management's claims of "rapid scaling" [6] Market Impact - Following the revelation of these delays, CoreWeave's market capitalization fell by approximately $14 billion, including a 16% drop on November 11 after the company lowered its guidance [2][6] - The stock's decline continued after a Wall Street Journal report highlighted the construction delays, resulting in substantial losses for shareholders [6] Legal Proceedings - The lead plaintiff deadline for the class action is set for March 13, 2026, and investors who purchased shares during the class period (March 28, 2025 – December 15, 2025) are encouraged to report their losses [4][5]

Core Viewpoint - Fermi Inc. is facing a securities class action lawsuit due to allegations of misrepresentation regarding the demand for its Project Matador AI data center and the stability of its primary tenant, leading to a significant stock price decline of nearly 34% following the termination of a $150 million funding agreement [1][2][7]. Allegations and Legal Proceedings - The lawsuit claims that Fermi's IPO materials exaggerated the demand for Project Matador to secure investor financing [3][7]. - The complaint highlights that Fermi failed to disclose the risks associated with relying on a single tenant for funding, which ultimately led to the termination of the Advance in Aid of Construction Agreement (AICA) [2][7]. - Following the announcement of the AICA termination on December 12, 2025, Fermi's stock price dropped by 33.8%, with shares trading as low as $8.59, representing a 59% decline from the IPO price of $21.00 [2][7]. Class Action Details - The class action lawsuit aims to represent investors who purchased Fermi shares during the October 2025 IPO or in the open market between October 1, 2025, and December 11, 2025 [6][7]. - The lead plaintiff deadline for the lawsuit is set for March 6, 2026 [6].

Core Viewpoint - Hagens Berman is investigating Ardent Health, Inc. for allegedly misleading investors regarding its revenue recognition systems and professional liability reserves, leading to significant financial repercussions and a class action lawsuit [2][4]. Group 1: Allegations and Financial Impact - Ardent Health reportedly assured investors of using "detailed reviews of historical collections" for valuing receivables, but later admitted to employing a "180-day cliff" for reserves, which contributed to a 33% stock collapse [2][5]. - The company experienced a $54 million increase in professional liability reserves due to settlements and ongoing litigation, alongside a $42.6 million revenue reduction attributed to a new accounting method for estimating receivables [5]. - Following the disclosures on November 12, 2025, Ardent's stock price fell nearly 34%, indicating a severe market reaction to the revelations [5]. Group 2: Legal Proceedings and Next Steps - A lead plaintiff deadline for the pending securities class action is set for March 9, 2026, with Hagens Berman actively advising investors who purchased shares between July 18, 2024, and November 12, 2025 [4][5]. - The lawsuit claims that Ardent's financial health was misrepresented, suggesting that the company's monitoring of receivables was a facade for a mechanical write-off system [3][4].

Core Viewpoint - A class action lawsuit has been filed against CoreWeave, Inc. and its executives, alleging that they misled investors about the company's ability to scale its AI infrastructure and meet revenue guidance [1][4] Allegations of Misrepresentation - The lawsuit claims that CoreWeave overstated its capacity to meet customer demand while downplaying operational risks associated with reliance on a single third-party data center supplier [2][8] - Significant delays at the Denton, Texas data center were concealed, with completion pushed back by several months due to construction hurdles, contradicting management's claims of "rapid scaling" [8] Financial Impact - Following the revelation of these delays, CoreWeave's market capitalization fell by approximately $14 billion, with a notable 16% drop in stock price on November 11 after the company lowered its guidance [2][8] - The lawsuit highlights that the company's ability to recognize revenue from its multibillion-dollar backlog was dependent on infrastructure that was reportedly not on track for timely completion [8] Legal Proceedings - Hagens Berman is actively advising investors who purchased CoreWeave shares during the class period from March 28, 2025, to December 15, 2025, and suffered losses [5] - The deadline for lead plaintiff submissions is set for March 13, 2026 [6]

Core Viewpoint - A securities class action lawsuit has been filed against BellRing Brands, Inc. and certain executives due to alleged misrepresentations regarding sales growth and competition, following disappointing earnings reports that significantly impacted share prices [1][4][6]. Group 1: Lawsuit Details - The lawsuit seeks to represent investors who acquired BellRing securities between November 19, 2024, and August 4, 2025 [1][3]. - Allegations include that BellRing's reported sales were primarily due to temporary inventory stockpiling by key customers, masking a decline in market share amid increasing competition [4][5]. - The lawsuit claims that strong sales results were misleading, as they reflected customers' excess inventory rather than genuine consumer demand [5][6]. Group 2: Market Reactions - Following the Q2 2025 earnings report on May 6, 2025, BellRing's share price fell by $14.88, a decrease of 19%, after the CFO indicated that key retailers had reduced their inventory levels [6][7]. - After the Q3 2025 earnings report on August 4, 2025, the share price dropped by $17.46, a decline of 33%, due to a disappointing sales outlook and concerns about competition [7][8]. - The firm Hagens Berman is investigating whether BellRing misled investors regarding consumer demand and inventory levels [8].

Core Viewpoint - Hagens Berman is investigating Trex Company, Inc. for potential violations of U.S. securities laws, focusing on undisclosed sales practices and inflated sales figures through overstocking its "pro channel" partners while claiming that its "level-loading" production strategy had stabilized inventory volatility [1][3]. Company Investigation Details - The investigation centers on whether Trex concealed excess inventory buildup at distributors, which may have misled investors regarding the company's sales performance [3]. - Trex's sales growth forecast for 2025 was revised down from +7% to approximately 0%, indicating a significant decline in expected performance [3]. - On November 4, 2025, Trex reported Q3 2025 net sales of $285 million, which was 5% below the midpoint of its guidance and represented a sequential decline of about 26% [4][5]. Market Reaction - Following the disappointing Q3 results and the revised sales outlook, Trex's stock experienced a 31% drop on November 5, 2025, resulting in a market cap loss of approximately $1.5 billion [3][5]. - The company's management had previously assured investors that their inventory strategy would reduce volatility, raising questions about their awareness of softening demand while pushing products into the market [6][7]. Key Metrics - The core metric of concern is the drastic cut in Trex's 2025 sales growth forecast, which was initially projected at 5% to 7% but was later adjusted to flat growth [3][5].

Core Viewpoint - Corcept Therapeutics experienced a significant decline in share price, dropping 50% after receiving a complete response letter from the FDA regarding its treatment relacorilant for hypercortisolism, leading to a loss of over $3.6 billion in market capitalization [1][3]. Company Overview - Corcept Therapeutics has previously promoted relacorilant's efficacy and commercial potential, claiming that clinical trial patients showed meaningful improvements in hypercortisolism symptoms [3]. - The company expressed confidence in achieving annual revenues of $3 billion to $5 billion from its hypercortisolism business within three to five years [3]. FDA Response - The FDA's complete response letter indicated that additional evidence of effectiveness was required for relacorilant, contradicting Corcept's previous assurances about the drug's progress toward approval [3]. - A report noted that the likelihood of loss of blood pressure control was 83% lower in the relacorilant group compared to placebo, which may have influenced the FDA's decision [3]. Legal Investigation - Hagens Berman, a national shareholder rights law firm, has initiated an investigation into whether Corcept misled investors regarding relacorilant's efficacy and commercial prospects [2][4]. - The firm is encouraging investors who suffered losses to come forward and discuss their rights [2][4].

Core Viewpoint - A securities class action lawsuit has been filed against Varonis Systems, Inc. and certain executives, representing investors who acquired Varonis common stock between February 4, 2025, and October 28, 2025, following a significant drop in share price due to disappointing financial results and guidance [1][3]. Company Performance - Varonis reported weaker than expected renewals and conversions from its on-premises subscription business to its software-as-a-service (SaaS) model, leading to a significant downward revision of its annual recurring revenue (ARR) [2][5]. - The company's Q3 2025 financial results missed both its own and consensus estimates, prompting a reduction in Q4 revenue and 2025 ARR guidance [5]. Market Reaction - Following the announcement of disappointing results, Varonis shares plummeted by approximately 48%, resulting in a loss of about $3.8 billion in market capitalization the next day [6]. Allegations of Misrepresentation - The lawsuit alleges that Varonis misled investors by making overly positive statements about its ability to convert on-prem customers to SaaS, while failing to disclose critical information regarding its actual conversion capabilities [4][6]. - The complaint claims that Varonis was not adequately prepared to transition its existing on-prem users to the SaaS model, which adversely affected its ARR growth potential [4].

Core Points - A securities class action lawsuit has been filed against CoreWeave, Inc. and certain executives, representing investors who acquired CoreWeave securities between March 28, 2025, and December 15, 2025 [1] - The lawsuit is a response to delays from a third-party data center developer, which has negatively impacted CoreWeave's share price [2] - Hagens Berman, a national shareholder rights firm, is investigating claims that CoreWeave misled investors, urging those who suffered losses to come forward [3] Financial Impact - The lawsuit alleges that CoreWeave made misleading statements regarding its ability to meet customer demand and revenue recognition from long-term contracts [4][5] - Following the Q3 2025 financial results announcement on November 10, 2025, CoreWeave reduced its full-year revenue guidance, attributing it to delays from a third-party data center developer [6] - The share price of CoreWeave fell by $36.11, a decrease of 34%, resulting in a loss of approximately $14 billion in market capitalization within a month [6] Allegations of Misleading Information - The complaint claims that CoreWeave overstated its capabilities and failed to disclose the risks associated with reliance on a single third-party data center supplier [5] - Reports indicated that the third-party supplier, Core Scientific, had been flagging delays since February 2025, which CoreWeave did not adequately communicate to investors [6]

Core Viewpoint - Hagens Berman is notifying investors about a securities class action against Fermi Inc. regarding misleading information related to tenant demand and funding for its "Project Matador" AI campus [1][6]. Summary by Relevant Sections Class Action Details - The lead plaintiff deadline for the class action is set for March 6, 2026 [2]. - The class period for the lawsuit is from October 1, 2025, to December 11, 2025 [2]. - The core allegation involves overstated tenant demand and undisclosed risks associated with the primary anchor tenant [2][6]. Stock Price Impact - Following the announcement of the termination of the AICA agreement by the First Tenant, Fermi's stock price dropped by 33.8% in a single day, falling to $10.09 per share, which is over 50% below its IPO price of $21.00 [4][7]. Project Matador Overview - Fermi's "Project Matador" is described as a multi-gigawatt energy and data center development aimed at supporting AI needs [3]. - The company had previously highlighted a $150 million Advance in Aid of Construction Agreement with an investment-grade tenant, which is now under scrutiny due to the tenant's exit [3][6]. Investigation Insights - Hagens Berman is investigating whether Fermi's management was transparent about the actual status of Project Matador [5].